OBJECTIVES: The aim of our study was to analyze the generic competition of medicaments containing the active substance montelukast sodium and to examine the cost-containment methods of the Hungarian National Health Insurance Fund Administration. METHODS: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration (2007-2013). We analized the turnover and price of the medicaments containing the active substance montelukast sodium. Accordingly our indicators were: consumer price, social insurance subsidy, patients’ co-payment and defined daily dose (DOT). RESULTS: The price of Singulair 10 mg tablets was 32 USD in October 2011, when the generics appeared, and it was reduced to 10 USD by the end of 2013. The generics started with a price 40% lower (for example Montelukast Teva 10 mg tablets: 19 USD, Eonic 10 mg tablets: 17 USD, Montelukast Sandoz 10 mg tablets: 19 USD), their price was diminished below 7.4 by the end of 2013 (for example: Montelukast Teva 10 mg tablets: 5.2 USD, Eonic 10 mg tablets: 5.8 USD, Montelukast Sandoz 10 mg tablets: 5.5 USD). The DOT increased gradually: In 2007 it was 1.7 million days, in 2010 6.3 million days and in 2013 it increased over 10 million days. The amount of the health insurance subsidy was 9.2 million USD in 2010. It reached its peak in 2011 (10.5 million USD) , in 2012 it was reduced to 7 million USD, in 2013 to 4.1 million USD, in all it is a setback of 61%. CONCLUSIONS: Following the introduction of generic drugs, the price of the medicaments containing montelukast sodium was significantly reduced. The annual health insurance subsidy was significantly reduced as well, while the DOT increased. The patients’ access to drugs containing montelukast sodium increased significantly.